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Abstract: The success of antifungal therapies is often hindered by the limited number of available
drugs. To close the gap in the antifungal pipeline, the search of novel leads is of primary importance,
and here the exploration of neglected plants has great promise for the discovery of new principles.
Through bioassay-guided isolation, uliginosin B and five new dimeric acylphloroglucinols (uliginosins
C-D, and 3′prenyl uliginosins B-D), besides cembrenoids, have been isolated from the lipophilic extract
of Hypericum mexicanum. Their structures were elucidated by a combination of Liquid Chromatography
- Mass Spectrometry LC-MS and Nuclear Magnetic Resonance (NMR) measurements. The compounds
showed strong anti-Candida activity, also against fluconazole-resistant strains, with fungal growth
inhibition properties at concentrations ranging from 3 to 32 µM, and reduced or absent cytotoxicity
against human cell lines. A chemogenomic screen of 3′prenyl uliginosin B revealed target genes that
are important for cell cycle regulation and cytoskeleton assembly in fungi. Taken together, our study
suggests dimeric acylphloroglucinols as potential candidates for the development of alternative
antifungal therapies.
Keywords: Hypericum; bioactive compounds; antifungal activity; acylphloroglucinols; structural
annotation; nuclear magnetic resonance spectroscopy; mass spectrometry; cytotoxicity; mechanism
of action
1. Introduction
Fungal infections are an increasingly serious problem especially in patients with immune
deficiencies caused by diseases like human immunodeficiency virus / acquired immunodeficiency
syndrome (HIV/AIDS) and cancer or by prolonged antibiotic treatments [1]. In particular, superficial or
invasive infections and chronic conditions caused by fungi annually affect millions of people, leading to
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gigantic treatment costs and a death toll of more than one million people per year [2]. Species belonging
to the genera Candida are among the most prevalent cause of invasive infections such as candidiasis
and candidemia [3,4]. The treatment outcomes of Candida infections are often impaired due to the low
availability of therapeutic options that are mainly restricted to the four antifungal classes azoles,
polyenes, echinocandins, and pyrimidine analogs [5]. Importantly, the success of the treatments is
threatened by the increasing emergence of multidrug-resistant pathogens, especially for the Candida
species C. glabrata, C. parapsilosis, C. lusitaniae, and C. tropicalis, with the estimation that more than
20–30% of candidemia cases involve fungal species with intrinsic resistance to either fluconazole
or echinocandins [6]. Overall, the outcomes of the available antifungal therapy are not satisfactory,
and therefore the discovery of new active compounds is a priority considering this alarming gap in
the anti-fungal pipeline [7]. The search for novel antifungal agents from medicinal plant sources [8,9]
offers a promising path to addressing this gap.
Among the natural compounds, dimeric phloroglucinols have recently attracted attention,
mainly because of their high degree of chemical diversity and their promising activity as cytotoxic
and antimicrobial drugs, which make these compounds a fascinating target for pharmacological
research [10].
Dimeric phloroglucinols are not universally biosynthesized in plants but mainly limited to
a small number of genera [10]. The plant genus Hypericum, including many medicinal species, is
considered as a prolific source of phloroglucinols. Despite the genus being mainly known for
the extensively investigated H. perforatum, an increasing number of publications is calling attention
towards less distributed or neglected species as well for the discovery of new antifungal formulations
and compounds [8–10]. Here, in particular, lipophilic extracts obtained from Hypericum species in South
America have shown inhibitory activity on the growth of human fungal pathogens [8–10] and their
properties have been suggested to be related to the presence of a class of dimeric phloroglucinols:
the dimeric acylphloglucinols (DAPs) [11] consisting of filicinic acid and phloroglucinol moieties [12]
Despite available studies documenting a great potential for this class of compounds as antimicrobial,
antidepressant and cytotoxic drug leads, DAPs are poorly investigated, maybe due to difficulties in
isolation, low yield, and instability [13].
In the search for new antifungal leads, we investigated the chemistry and the antifungal properties
of extracts from Hypericum mexicanum L., a neglected species [14] that is part of a recent and rapid
radiation in the montane páramos of the Colombian and Venezuelan Andes [12,15] where it is
a common weed and used by the native populations for the manufacture of handicraft products,
and remedies for the treatment of wounds and burns (aerial parts) and muscle aches and kidney
disease (roots) [16]. However, literature on medicinal applications of H. mexicanum extracts is very
scarce. Corso-Barragan et al. (2017) [17], reported the antibacterial activity of the ethanolic extract of
the plant, while essential oils of H. mexicanum have been suggested as potential repellents in plant pest
control [18].
Our study leads to the description of the phenolic profile of the whole plant, and to the isolation
and characterization of five novel DAPs that showed selective inhibitory properties on fungal growth
and no cytotoxicity on human cell lines. Notably, the first evidence for the mechanism of action
of a highly active DAP, a sarothralen B-like compound, is reported as deduced from the output of
a chemogenomic screening.
2. Results and Discussion
2.1. Chemical Profile of Hypericum Mexicanum
Crude extracts obtained from leaves, stems and roots of H. mexicanum were chemically
characterized by the identification and quantification of 34 low molecular weight polyphenols as
reported in Table 1. Five metabolites (3,5-dihydroxy benzoic acid, quercetin-3-glucoside, procyanidin B2,
kaempferol-3-glucoside and phlorizin) were distributed in all of the organs, while three only in the aerial
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parts, and five compounds detected in both leaves and roots but not in stems. Leaves extract was
the richest in phenols and the more abundant compounds were procyanidin B2 (117.37 ± 4.02 µg/g);
quercetin (97.07 ± 1.01 µg/g); isorhamnetin-3-glucoside (96.58 ± 5.01µg/g); quercetin-3-glucoside
(86.45 ± 3.03 µg/g); and epicatechin (36.17 ± 2.02 µg/g). The chemical profile of H. mexicanum resembles
those of the closely phylogenetically related species H. laricifolium [8], strengthening our previous
observation that chemical profiles in Hypericum seem to mirror evolutionary relationships of species.
Table 1. Phenolic profile of extracts from Hypericum mexicanum.
Compound Stem LeavesMethanol Extracts * Roots
Leaves
Chloroform Extract *
Caffeic acid nd 0.16 ± 0.10 nd nd
3,5-dihydroxy benzoic acid 0.11 ± 0.05 2.02 ± 0.30 0.11 ± 0.05 0.13 ± 0.03
Gallic acid nd nd nd nd
Kaempferol nd 1.78 ± 0.09 0.01 ± 0.01 0.40 ± 0.07
Quercetin-3-glucuronide nd 0.09 ± 0.01 nd 0.21 ± 0.04
Quercetin nd 97.07 ± 1.01 0.06 ± 0.01 2.87 ± 0.60
Quercetin-3-glucoside 0.05 ± 0.01 86.46 ± 3.03 0.04 ± 0.01 nd
Kaempferol-3-glucuronide nd nd nd 0.01 ± 0.01
Isorhamnetin 0.02 ± 0.01 6.73 ± 0.02 nd 0.03 ± 0.01
Syringetin-3-glucoside nd nd nd nd
Isorhamnetin-3-glucoside 0.12 ± 0.01 96.58 ± 5.02 nd 0.13 ± 0.03
Myricetin nd 1.80 ± 0.10 nd nd
Catechin nd nd nd nd
Epicatechin 0.09 ± 0.03 36.17 ± 2.01 nd nd
Gallocatechin nd 0.12 ± 0.05 nd nd
Epigallocatechin nd nd nd nd
Procyanidin B1 nd 2.64 ± 0.30 nd 0.09 ± 0.03
Procyanidin B2 0.24 ± 0.03 117.37 ± 4.02 2.72 ± 0.31 0.19 ± 0.08
cis-piceid nd 0.11 ± 0.06 nd nd
Vanillic acid nd 0.47 ± 0.12 0.01 ± 0.01 0.08 ± 0.01
Esculin nd 0.04 ± 0.01 nd 0.01 ± 0.01
Neochlorogenic acid nd 6.98 ± 0.50 0.01 ± 0.01 nd
Cryptochlorogenic acid nd 0.36 ± 0.02 nd nd
Chlorogenic acid nd nd nd nd
Luteolin nd 2.81 ± 0.81 nd 0.44 ± 0.09
Luteolin-7- glucoside nd 0.42 ± 0.05 nd traces
Quercetin-3-arabinoside nd 2.39 ± 0.81 nd nd
2,6-dihydroxy benzoic acid nd nd nd nd
p-hydroxybenzoic acid nd 1.31 ± 0.31 0.02 ± 0.01 0.04 ± 0.01
Cinnamic acid nd 0.08 ± 0.01 nd 0.13 ± 0.01
Naringenin-7-glucoside nd 0.12 ± 0.07 nd 1.74 ± 0.30
Coniferyl alcohol nd nd nd nd
Kaempferol-3-glucoside 0.01 ± 0.01 5.40 ± 1.01 0.01 ± 0.01 nd
Phlorizin 0.02 ± 0.01 4.51 ± 0.51 0.03 ± 0.01 nd
* Data expressed as µg/g extract.
2.2. Antifungal Activity of H. Mexicanum Extracts and Chemical Analysis of the Chloroformic Extract
The extract from the aerial parts was tested against two environmental strains of S. cerevisiae and
3 clinical strains of C. albicans showing encouraging inhibition properties at relative low concentration
(44.70 µg/mL for S. cerevisiae and 63.50 µg/mL for C. albicans) (Table S1). To better understand the nature
of the active principles present in the crude extracts, leaves of H. mexicanum were additionally subjected
to extraction with chloroform, obtaining an extract enriched in molecules with different polarity that
was tested against a broader panel of Candida spp. clinical isolates (Table 1).
The chloroform extract showed the strongest antifungal activity against all tested strains when
compared with the methanolic extract (Table 2 and Table S2).
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Table 2. Anti-Candida activity of leaves extracts from H. mexicanum.
Strain (N◦ Tested) Chloroformic
Methanol
MIC50 µg/mL *
C. albicans (4) 27 64
C. parapsilosis (2) 16 125
C. glabrata (2) 11 45
C. lusitaniae (2) 10 32
C. tropicalis (1) 23 >125
C. pararugosa (1) 32 >125
C. deformans (1) 32 >125
* Data are expressed as geometric mean.
Chemical analysis showed low amounts of phenols in comparison with the methanolic extract
(Table 1), suggesting that the observed antifungal properties could be attributed to the presence of
other compounds with more lipophilic characteristics in line with what was found for other Hypericum
species phylogenetically close to H. mexicanum [9,19,20].
2.3. Bioassay-Guided Isolation and Characterization of Antifungal Principles
To better define the antifungal properties of the lipophilic extracts, the aerial parts of H. mexicanum
were extracted with hexane and subsequently partitioned with n-hexane and water. The n-hexane
soluble compounds were separated by silica-gel column chromatography obtaining two major fractions:
Fraction I appeared to be mainly composed of a single species according to HPLC chromatogram
and UV spectrum (Figure S1). NMR analysis of fraction I confirmed the presence of a main terpenoid
compound (93%), cembrene, and of a minor terpenoid compound (7%), isocembrene (data not shown).
Fraction II was composed of six compounds as revealed by HPLC chromatogram and UV spectrum
(Figure S2). The anti-fungal test outlined the fraction II as the most active in the inhibition of Candida
growth as showed in Table 3).
Table 3. Anti-Candida activity of fractions collected after chromatographic separation of H. mexicanum
lipophilic extract.
Strain
Fraction I Fraction II Fluconazole
MIC50 (µg/mL)
C. albicans MFB 051-1 >50 <32 64.0 ± 1.0
C. albicans MFB032-1 >50 32 ± 1.0 0.5 ± 0.1
C. albicans MFB076-1 >50 32 ± 0.5 >64
C. albicans MFB008 MM1 >50 <4 >64
C. albicans YMS 102-2 >50 <<4 >64
C. albicans YMS100-3 >50 16 ± 0.5 0.5 ± 0.1
C. lusitaniae MFB037 N1 >50 8 ± 1.0 0.5 ± 0.2
C. lusitaniae YMS 100-16 >50 <4 0.3 ± 0.1
C. parapsilosis MFB014
CD7 >50 4 ± 0.5 >64
C. parapsilosis MFB070
N1 >50 125 ± 1 >64
C. parapsilosis YMS 100-1 >50 4 ± 0.5 2 ± 0.5
C. pararugosa MFB037 N3 >50 8 ± 0.5 0.1
MIC50 values are expressed as means ± standard deviation of three independent experiments.
Among the latter, we isolated after extensive chromatographic purification both the known
dimeric acylphloroglucinols uliginosin B (1) and its new analogues uliginosin C (2), uliginosin D
(3) where the 2-methyl-1-oxopropyl moiety of 1 are replaced by the 2-methyl-1-oxobutyl moiety at
C-8′ in 2 and both at C-6 and C-8′ in 3. We also isolated the corresponding 3′ prenylated dimeric
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acylphloroglucinols analogues of 1-3 which we named 3′prenyl uliginosin B (4), 3′prenyl uliginosin C
(5) and 3′prenyl uliginosin D (6). Compounds structures are reported in Figure 1.
Figure 1. Structural elucidation.
The structural elucidation of uliginosin C (2) was straightforward due to the strong structural
resemblance with the well-known uliginosin B [13], also present in our extract.
In particular, high resolution mass measurements carried out by ESI in negative ion mode
(HR-ESI-MS) of 2 showed a pseudomolecular ion peak [M −H]− at m/z 511.2315 ± 0.0010, consistent
with a molecular formula of C29H35O8 (calculated exact mass 511.2337) for the anionic form of 2,
thus speaking for the presence of one methylene (–CH2–) more in 2 with respect to 1. Extensive
2D-NMR measurements on 2 allowed us to establish that this methylene unit must be part of one ethyl
moiety at C-11′ replacing the methyl analogue in 1, or in more general terms, we established that 2 is
the 2-methyl-1-oxobutyl analogue of 1. Whereas from one side the presence of this moiety could be
easily inferred by the analysis of the 1D-NMR spectrum (the coupling pattern of the secondary proton as
expected was found as a sextet), from the other side Heteronuclear Multiple Bond Correlation (HMBC)
correlations indicated that the 2-methyl-1-oxobutyl moiety was linked to C-11′, leaving the remaining
2-methyl-1-oxopropyl unit linked to C-10. In particular, the proton at δH 3.83 with a sextet pattern
(J = 6.7 Hz) was found to be 1J hetero-correlated (Heteronuclear Single Quantum Coherence, HSQC)
with 13C resonance at δC 45.7; more important, in our HMBC measurements it was found to be
strongly (3J) long-range hetero-correlated to δC 11.9 (methyl carbon of the ethyl moiety) and to δC 104.2
(easily assigned to C-8′) and to show weak (2J) hetero-correlations with δC 26.7 (attributable to C-14′)
and with δC 210.8 (C-11′ carbonyl group). A full 1H and 13 C-NMR assignment of 2 is reported in
Table 4. In order to confirm assignments made in CDCl3, further NMR experiments of 1 were also
recorded in acetone-d6 (not reported).
The structure is also fully supported by tandem ESI MS experiments that showed characteristic
fragments ions at m/z 235 and 275 following the breaking of the C6′-C7 bond and the fragment ion at
m/z 223 following the breaking of the C2–C7 bond. When we compare the results of similar MS/MS
fragmentation of uliginosin B (1) leading to fragment radical ions at m/z 235 and 261 (via C6′–C7
homolytic bond breaking) and fragment ion at m/z 223 (via C2–C7 bond breaking), our results in 2 are
only compatible with a structure where the 2-methyl-1-oxobutyl unit is installed at C-8′, as drawn in
Figure 2.
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Table 4. NMR spectroscopic data for compounds 2 and 5 (400 MHz, CDCl3, 300K).
Signal
1 H-NMR
Compound 2
1 H-NMR
Compound 5
13 C-NMR
Compound 2
13 C-NMR
Compound 5
1 199.4 s 199.4 s
2 107.1 s 107.1 s
3 171.6 s 171.6 s
4 44.3 s 44.3 s
5 187.3 s 187.3 s
6 111.2 s 111.4 s
7 3.55 (2H; br d; 16.9) 3.54 (2H; br d; 16.9) 16.9 br t 17.0 t
8 1.45 (3H; s) 1.45 (3H; s) 24.2 brq 19.1 brq
9 1.53 (3H; s) 1.53 (3H; s) 25.4 brq 19.5 brq
10 4.21 (1H; septet; 6.8) 4.21 (1H; septet; 6.8) 210.9 s 210.8 s
11 36.6 d 36.6 d
12 1.18 (3H, s) 1.18 (3H, s) 19.3 brq 19.3 brq
13 1.18 (3H, s) 1.18 (3H, s) 16.7 brq 20.5 brq
2′ 78.1 s 79.5 s
2′-Me
1.48 s 1.47 s 27.7 brq 27.5 brq
1.48 s 1.23 28.1 brq 20.5 brq
3′ 5.44 (d, 10.1) 1.71 (1H, m) 124.6 d 40.8 d
4′ 6.70 (d,10.1)
2.83 (1H; dd,5.4,17.1)
117.3 d 22.7 t2.17 (1H; dd 10.2,17.1)
5′ 155.4 s 155.3 s
6′ 108.1 s 107.1 s
7′ 162.2 s 161.6 s
8′ 104.2 s 104.7 s
9′ 159.3 s 161.4 s
10′ 103.6 s 102.4 s
11′ 210.8 s 210.7 s
12′ 3.81(1H; septet; 6.8) 3.89(1H; septet; 6.8) 45.7 d 38.9 d
13′ 1.18 (3H; s) 1.18 (3H; s) 19.1 q 19.1 q
14′ 1.42/1.88 (2H; m) 1.42/1.88 (2H; m) 26.7 t 27.5 t
15′ 0.94 (3H; t; 6.7) 0.94 (3H; t; 6.7) 11.9 q 11.9 q
1′’ 2.32/1.81 (2H; m) 29.4 t
2′’ 5.19 (1H, br t, 6.8) 122.1 d
3′’ 133.1 s
4′’ 1.73 (3H; brs) 25.8 q
5′’ 1.62 (3H. brs) 17.2 q
High-Resolution Quadrupole-Time of Flight Mass Spectrometry with Electrospray Ionization on
a (HR-ESI-QTOFMS) of compound 3 showed a pseudomolecular ion peak [M−H]− at m/z 525.2483± 0.0010,
consistent with a molecular formula of C30H37O8 (calculated exact mass 525.2493) for the anionic form
of 3, thus speaking for the presence of two methylenes (–CH2–), more in 3 with respect to 1; our guess
of the presence in 3 of the 2-methyl-1-oxobutyl moiety both at C-6 and C-11′ was promptly confirmed
by the results of tandem ESI MS (Figure 2) where the characteristic fragment radical ions were detected
at m/z 249 and 275 (via C6′–C7 bond breaking) and at m/z 237 (via C2–C7 bond breaking). Although 3
was isolated only in a low amount preventing extensive NMR measurements, its 1H-NMR spectrum was
in full agreement with the proposed structure showing two characteristic multiplets at δH 3.82 (H-12′,
sextet J = 6.7) and at δH 4.06 (H-11, sextet J = 6.7). Difficulties in NMR interpretation mainly derive
from the expected keto−enol tautomerization of the cyclohexenone moiety in organic solvent solutions,
a process that significantly complicates the NMR spectra of these metabolites, often hindering a complete
assignment of the signals. As already observed for uliginosin B, even after extensive reverse phase HPLC
purifications, in our hands these dimeric acylphloroglucinols are accompanied by a significant relative
amount (20–25%) of their iso-analogues deriving from the closure of isoprenyl chain at C-10′ not at
the oxygen atom at C-9′ but, instead at the oxygen atom at C-5′. As previously reported in iso-uliginosin
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B [13], in the 1H-NMR spectra of 2 and 3 besides major resonance attributable to the olefinic proton signals
at C-3′ and C-4′, small resonances at slightly deshielded (+0.025 ppm for H–C3′) or slightly shielded
chemical shift (−0.035 ppm for H–C-4′) also appear whilst all the other resonances of these iso-analogues
are almost superimposable to the major uliginosin C (2) and uliginosin D (3).
Figure 2. Observed ion fragments upon MS-MS fragmentation of the parent [M-H]- of uliginosins C (2)
and D (3).
HR-ESI-MS of 4 showed a pseudomolecular ion peak [M −H]− at m/z 567.2941 ± 0.0010, consistent
with a molecular formula of C33H43O8 [calculated exact mass 567.2943] for the anionic form of 4,
thus containing an isoprenyl chain (C5H10) more than uliginosin B (1). In the 1H-NMR spectrum of 4,
the most prominent feature was the absence of the olefinic protons at C-3′ and C-4′ of uliginosin B-D.
After extensive 2D NMR measurements, we unambiguously establish that this prenyl chain was linked
to C-3′, leaving C-4′ as a saturated sp3 carbon atom, as drawn in Figure 3.
Figure 3. Observed ion fragments upon MS-MS fragmentation of the parent [M−H]− of prenyl-uliginosins
B(4), C(5), and D(6).
This outcome was also in agreement with tandem Mass Spectrometry with Electrospray Ionization
(ESI-MS/MS) measurements showing fragment radical ions deriving from the C6′–C7 bond breaking
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at m/z 235 and 331 and from the C2–C7 bond breaking at m/z 223 (Figure 3). The key 1H-13C NMR
hetero-correlations are those deriving from long range couplings of C-2′ (singlet at δC 79.5) both with
3H-C-2′ (broad singlets at δH 1.47 and 1.23) and with diastereotopic protons at C-4′ (δH 2.83 dd, 5.5,
17.4; δH 2.17 dd, 10.3, 17.2). On the other hand, strong couplings with the same protons were also
found with C-3′ (doublet at δC 40.8). Since in the HSQC spectrum C-3′ was found carbon-coupled to
a broad multiplet at δH 1.71, which, in turn, in the COSY experiment was found proton-coupled to
methylene geminal protons both at C-4′ and C-1” (broad multiplets at δH 2.32 and 1.81), the position of
the targeted isoprenyl chain must be at C-3′ (equatorial position) of the dihydropyran ring. Although
the structure of 4 has recently been reported and named denudatin A [21], two critical issues emerge
from this report. First of all, some NMR assignments are inconsistent and incorrect attributed. In fact,
(i) allylic protons at C-1” reported there as br singlet at δH 1.48 must be assigned to the diastereotopic
signals at δH 2.32 and 1.81, being 3J homonuclear coupled to the olefinic proton of the prenyl chain;
(ii) the geminal methyls at C-2′ (quartets δC 27.5/δH 1.47 and δC 20.5/δH 1.23) show very similar
long range couplings to C-2′ and C4′. Second, and most important, the name denudatin A should
not have been used for this compound, since it had already been given several years ago (1980)
to another isolated natural compound isolated from Magnolia denudata Desr [22]. Surprisingly enough,
a structure-based search of 4 in the database Scifinder [23] does not lead to any literature reference
related to acylphloroglucinols, including reference [21]; in contrast, searching the same database with
the name-based keyword “denudatin A” revealed 17 literature references, of which just one [21]
was related to this prenylated acylphloroglucinol 4. However, and really noteworthy, the CAS Registry
Number (87402-87-7) assigned to 4 is wrong, being the same as that assigned to the previously
reported neolignan metabolite from M. denudata. The structural elucidation of prenyl-uliginosin C
(5) was straightforward due to the strong structural resemblance with its analogue 4. In particular,
HR-ESI-MS of 5 (Table 5) showed a pseudomolecular ion peak [M − H]− at m/z 581.3111 ± 0.0010,
consistent with a molecular formula of C34H45O8 (calculated exact mass 581.3120) for the anionic form
of 5, thus indicating the presence of one methylene (-CH2-) more in 5 with respect to 4. 1D and 2D-NMR
spectra of 5 allowed us to establish that this methylene unit must be part of one ethyl moiety at C-11′,
fixing 5 as the 2-methyl-1-oxobutyl analogue of 4, in full agreement with the results of tandem-MS
measurements (Figure 3). HR-ESI-MS (Table 5) of prenyl-uliginosin B (6) showed a pseudomolecular ion
peak [M − H]− at m/z 595.3267 ± 0.0010, consistent with a molecular formula of C35H47O8 [calculated
exact mass 595.3276] for the anionic form of 6, thus bearing two methylenes (–CH2–) more than
prenyl-uliginosin B (4). On the other hand, the presence in 6 of the 2-methyl-1-oxobutyl moiety both at
C-6 and C-11′ was fully supported by the results of tandem ESI-MS (Figure 3), where the characteristic
fragment radical ions were detected at m/z 249 and 345 (via C6′–C7 bond breaking) and at m/z 237
(via C2–C7 bond breaking). Although 6 was isolated in a very low amount and pure enough for
extensive NMR measurements, the 1H-NMR spectrum was in full agreement with the proposed
structure showing two characteristic multiplets at δH 3.82 (H-12′, sextet J =6.7) and at δH 4.06 (H-11,
sextet J =6.7).
Table 5. High resolution MS data for parent and daughter ions of acylphloroglucinols 2–6 as measured
by HR-ESI-QTOFMS.
Compound ESI (−)Ion Type
Molecular
Formula
Calculated
Exact Mass (m/z)
High Resolution
Mass Measurement
(±0.0010)
2
[M − H]− C29H35O8 511.2337 511.2315
Fragment-ion C2-C7 C12H15O4 223.0976 223.0978
Fragment-ion C6′-C7 C13H15O4 235.0976 235.0978
Fragment-ion C6′-C7 C16H19O4 275.1289
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Table 5. Cont.
Compound ESI (−)Ion Type
Molecular
Formula
Calculated
Exact Mass (m/z)
High Resolution
Mass Measurement
(±0.0010)
3
[M − H]− C30H37O8 525.2493 525.2483
Fragment-ion C2-C7 C13H17O4 237.1132 237.1133
Fragment-ion C6′-C7 C14H17O4 249.1132
Fragment-ion C6′-C7 C16H19O4 275.1289 275.1293
4
[M − H]− C33H43O8 567.2943 567.2941
Fragment-ion C2-C7 C12H15O4 223.0976 223.0978
Fragment-ion C6′-C7 C13H15O4 235.0976 235.0978
Fragment-ion C6′-C7 C20H27O4 331.1915 331.1918
5
[M − H]− C34H45O8 581.3120 581.3111
Fragment-ion C2-C7 C12H15O4 223.0976 223.0978
Fragment-ion C6′-C7 C13H15O4 235.0976 235.0978
Fragment-ion C6′-C7 C21H29O4 345.2071
6
[M − H]− C35H47O8 595.3276 595.3267
Fragment-ion C2-C7 C13H17O4 237.1132 237.1141
Fragment-ion C6′-C7 C14H17O4 249.1132 249.1120
Fragment-ion C6′-C7 C21H29O4 345.2071 345.2075
2.4. Antifungal and Cytotoxic Properties of Isolated Compunds
The inhibitory activity of the isolated compounds was tested against clinical isolates of Candida
strains, and their cytotoxicity was evaluated against the human skin fibroblast Hs27 cell line (ATCC ®
CRL-1634™, Manasas, VA, USA) and against peripheral blood mononucleate cells (PBMC). All isolated
compounds showed strong antifungal activity against Candida species at concentrations ranging from
3 to 32 µM (Table S3). The uliginosin B-like and sarothralen B-like compounds 2 and 4 were selected
for in-depth biological analysis. Both compounds showed a potent antifungal activity against a broad
panel of Candida species and, in particular, they out-competed the main antifungal fluconazole against
azole-resistant C. albicans and C. parapsilosis (Table 6).
Table 6. Anti-Candida activity of two major isolated compounds.
Candida Strain Uliginosin C 3′ Prenyl Uliginosin B Fluconazole
MIC50 (µM)
C. albicans MFB 076N1 16 ± 0.5 15 ± 1 208 ± 2
C. albicans MFB 008 MM1 6 ± 0.2 3 ± 0.2 208 ± 2
C. albicans MFB YMS 100-3 >32 >30 1.6 ± 0.1
C. albicans MFB YMS 102-2 8 ± 0.7 4 ± 0.3 >208
C. parapsilosis MFB YMS 100-1 32 ± 1 6 ± 0.6 6 ± 0.5
C. parapsilosis MFB 014 CD7 32 ± 1 30 ± 2 >208
C. parapsilosis MFB 070 N1 >32 >30 >208
C. lusitaniae MFB YMS 100-16 >32 30 ± 2 0.8 ± 0.2
C. lusitaniae MFB 037 N1 8 ± 0.2 30 ± 1 1.6 ± 0.5
C. pararugosa MFB 037 N3 8 ± 0.7 15 ± 2 0.4 ± 0.0
C. glabrata MFB004 16 ± 1 4 ± 0.1 0.13 ± 0.0
C. glabrata MFB005FS4 8 ± 0.4 6 ± 0.1 0.13 ± 0.0
MIC50 values are expressed as means ± standard deviation of three independent experiments.
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Additionally, both compounds showed no or only reduced cytotoxicity when tested against
normal human cell lines at concentrations that were twice as high as the highest measured antifungal
activity (Figure 4).
Figure 4. Evaluation of the cytotoxicity of uliginosin C (C2) and 3′prenyl uliginosin B (C4), measured using
the WST-8 conversion assay, on normal human cell lines. The metabolic activity is given as the endpoint
of toxicity in human peripheral mononucleate cells (PBMC) and human skin fibroblast cell line (Hs27),
following 24 h exposure to the compounds. Values represent standard error of the mean (n = 3). The results
were analyzed by Student’s t-test. No statistically significant differences were detected.
2.5. Mechanism of Action Analysis
As sarothralen B-like compounds have not yet been described as antifungals, we subjected
3′prenyl uliginosin B to a chemogenomic screen to identify possible molecular targets (Figure 5).
Chemogenomic profiling allows characterizing the global cellular response to a compound of
interest and to identify all gene products that functionally interact with this compound by using
a genome-wide competitive growth assay [24]. Here, each member of a molecularly bar-coded pooled
yeast deletion collection is grown in a single culture, in either the presence or absence of 3′ prenyl
uliginosin B, thus allowing one to record their growth fitness in parallel. Hence, deletion strains
having a reduced fitness when compared to the control indicate that the respective gene deletion grants
sensitivity to the compound. This chemogenomic screen revealed deletion strains highly sensitive
against 3′ prenyl uliginosin B that were heterozygous for genes involved in cell cycle progression,
translation, protein folding and maturation, sterol biosynthesis and uptake, telomere and chromosome
maintenance, and oxidative stress resistance (Table S4). The most sensitive mutant was heterozygous
for the chaperonin CCT5, a subunit of the eukaryotic cytosolic chaperonin containing TCP-1 (CCT).
CCT is a multi-subunit protein complex that assists the folding of several proteins important for cell
cycle regulation, cytoskeleton assembly, and chromatin remodeling [25,26]. It also plays a role in
the formation of stress granulates [27] and assists the proper assembly and function of the septin
ring [26]. All CCT genes are essential in yeast and small perturbations can lead to serious growth
defects or loss of viability [28].
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Figure 5. Chemogenomic screen. The pool of tagged 5936 deletion mutants was grown for 20 generations in
the presence of 3′prenyl uliginosin B (150µg) and 1% DMSO (control). Log2 ratio (control intensity/treatment
intensity) was calculated and plotted as a function of gene. The genome-wide readout of heterozygous
highly sensitive strains included CCT5, a subunit of the cytosolic chaperonin CCT ring complex that is
required for the assembly of actin and tubulins (red dots: logFC > 1.5 and p-value < 0.01).
Notably, the interactions between CCT and its major folding substrates actin and tubulin seem to be
sequence-specific [29], which would make it an exciting novel drug target, especially due to the evidence
that changes in expression of a CCT subunit can block hyphal morphogenesis in Candida [30]. Hyphal
growth is regarded as an important virulence factor in Candida species and inhibiting the yeast-to-hyphal
switch during early stages of infection can significantly increase the survival of the host [4,31].
3. Materials and Methods
3.1. Plant Material
Plant material used in this study was collected in July 2012 in the vicinity of Bogotá in the eastern
Cordillera of the Colombian Andes (loc. 4.771647, -73.874224) and was identified as species Hypericum
mexicanum L. using the identification key provided in the monograph Hypericum [32]. Voucher
specimens have been deposited in the herbarium of the Universidad de los Andes (ANDES; coll. Nürk,
Dreer & Rojas Colmenares 934, det. N.M.Nürk), Colombia.
3.2. Preparation of Plant Extracts
For the investigation of the phenolic profile of Hypericum mexicanum (Table 1), roots, leaves, and
stems have been left to air-dry till reaching constant weight. Dried plant biomass (10 g per each sample)
was powdered by grinding and extracted with methanol (drug/solvent ratio = 1:20 w/v) by maceration
(3 × 24 h) in the dark.
After extraction with methanol, a batch of dried leaves biomass was subjected to further extraction
with chloroform (drug/solvent ratio = 1:20 w/v) in order to obtain an extract characterized by non-polar
compounds to be tested for antimicrobial activity.
For compound isolation, dried H. mexicanum leaves and stems (500 g) were powdered by grinding
and extracted with hexane (drug/solvent ratio = 1:20 w/v) by maceration (3 × 24 h) in the dark.
The hexane extract was further extracted with 70% acetonitrile in acid water (doubly distilled water
added with 0.1% formic acid). The obtained extracts were evaporated to dryness, weighed, and stored
at −20 ◦C until further use. Extracts were resuspended in 50% methanol/water and filtered with sterile
(0.2 µm) PTFE filters, prior to analysis.
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3.3. Chemicals
Methanol and acetonitrile were of LC-MS grade and were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Milli-Q water was used for the chromatography. The majority of the chemical standards
are commercially available and were obtained from different suppliers [33].
Cis-piceid was produced by photochemical isomerization of the trans form, as described by
Mattivi et al. (1995) [34].
3.4. LC-MS Analysis
Analysis of phenolic metabolites was performed as previously described [33] with few modifications.
A Waters Acquity UPLC system (Milford, MA, USA) consisting of a binary pump, an online vacuum
degasser, an autosampler, and a column compartment was used. Phenolic compounds were separated at
a temperature of 40 ◦C on a Waters Acquity HSS T3 column 1.8 µm, 150 mm × 2.1 mm (Milford, MA,
USA). The mobile phase was composed of component A (0.1% formic acid in water) and component B
(0.1% formic acid in acetonitrile). The flow was set to 0.4 mL/min, and the gradient profile was: 0 min,
5% B; from 0 to 3 min, linear gradient to 20% B; from 3 to 4.3 min, isocratic 20% B; from 4.3 to 9 min,
linear gradient to 45% B; from 9 to 11 min, linear gradient to 100% B; from 11 to 13 min, wash at 100% B;
from 13.01 to 15 min, then re-equilibrated to the initial conditions of 5% B. The injection volume was 2 µL
for both sample and standard solutions. Each sample was analyzed in triplicate. After each injection,
the needle was rinsed with 600 µL of a weak washing solution (water/methanol, 90:10) and 200 µL
of a strong washing solution (methanol/water, 90:10). Samples were kept at 6 ◦C during the analysis.
Mass spectrometry detection was performed on a Waters Xevo TQMS (Milford, MA, USA) instrument
equipped with an electrospray (ESI) source. Capillary voltage was 3.5 kV in positive mode and −2.5 kV
in negative mode; the source was kept at 150 ◦C; the desolvation temperature was 500 ◦C; cone gas
flow, 50 L/h; and desolvation gas flow, 800 L/h. Further MS parameters are reported in Vrhovsek et al.
(2012) [33].
Quantification was done using Waters MassLynx 4.1 and TargetLynx software (Waters, Milford,
MA, USA). All compounds were quantified via external calibrations.
3.5. Compound Isolation and Mass Spectrometric Conditions
The hexane extract was subjected to a solid phase extraction SPE (direct phase, SI), using
hexane/ethyl acetate as mobile phase in a gradient elution (starting with 100% hexane and reaching up
to 1:1 hexane/ethyl acetate). Several fractions were collected and spotted into a TLC plate (TLC Silica Gel
60 T254, from Merck, Germany); they were chromatographically resolved with a mobile phase consisting
of hexane/ethyl acetate 9:1, and the analytes were visualized by carbonization with an aqueous solution
of 10% cerium (IV) sulfate and 15% H2SO4. Alike fractions were grouped together, obtaining two major
fractions, and the collected pooled fractions were subjected to further analysis, including NMR and
LC-MS. The LC-MS measurements were carried out using a High Performance LC system (CBM-20 A,
equipped with the binary pump LC-20AB, Shimadzu, Milano, Italy) working in reversed phase with
a Kinetex C18 column (100 Å pore size, 4.6 mm ID, 2.6 µm particle size, and 10 cm length, Phenomenex,
Bologna, Italy). The mobile phase was composed of solvent A, methanol:water (7:3 v/v) with 0.5%
formic acid, and solvent B, methanol with 0.5% formic acid. The gradient elution program was tailored
to each of the fractions investigated:
• Fraction I: Isocratic elution, 70% B and 30% A, flux: 0.9 mL/min;
• Fraction II: Gradient elution, starting with 75% B and reaching 85% B in 20 min.
These compositions were maintained until 30 min. The flux was set to 1.1 mL/min. The effluent
from the column was split in two, and simultaneously detected by both an UV/VIS spectrometer
(Shimadzu, Milano, Italy) and by an API 3000 QQQ mass spectrometer equipped with an electrospray
ion source (ESI) (AB Sciex, New York, NY, USA). Both positive and negative ion scans were acquired,
and the mass spectrometer was operated in full scan mode.
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Isolated compounds were analyzed by Waters Acquity UPLC coupled via an electrospray ionization
(ESI) interface to a Synapt HDMS QTOF MS (Waters, Manchester, UK) operating in W-mode and
controlled by MassLynx 4.1 was used. All samples were analyzed on a reversed phase (RP) ACQUITY
UPLC 1.8 mm, 2.1 µm × 150 mm HSS T3 column (Waters, Milford, MA, USA) at 30 ◦C with gradient
elution starting isocratic from 100% A (water, 0.1% formic acid) from 0 till 6 min, then increasing
linearly over 56 min to 100% B (methanol, 0.1% formic acid), where it was held isocratic until 60 min,
with 0.3 mL/min flow rate. Injection volume was 5 mL and the samples were kept at 4 ◦C throughout
the analysis. Mass spectrometric data were collected in negative ESI mode over a mass range of 50 to
3000 amu with scan duration of 0.3 s in centroid mode and in high energy. The transfer collision energy
and trap collision energy were set at 30 V and 6 V for high energy acquisition respectively. The source
parameters were set as follows: 2.5 kV for negative scan, sampling cone 25 V, extraction cone 3 V, source
temperature 150uC, desolvation temperature 500 ◦C, desolvation gas flow 1000 L/h, and nebulizer gas
50 L/h. External calibration of the instrument was performed at the beginning of each batch of analysis
by direct infusion of a sodium formate solution (10% formic acid/0.1 M NaOH/Acetonitrile at a ratio
of 1/1/8) by controlling the mass accuracy from 40 to 2000 m/z (less than 5 ppm) and mass resolution
(over 14,000, full width at half maximum, FWHM). LockMass calibration was applied using a solution
of leucine enkephaline (0.5 mg/L, m/z 554.2620 for negative ion mode) at 0.1 mL/min.
3.6. NMR Analysis
The NMR measurements were performed with a Bruker-Avance 400 MHz spectrometer (Bruker
BioSpin, Rheinstetten, Germany) operating with a stationary magnetic field of strength 9.4 T and
equipped with a 5 mm BBI probe; the 90◦ proton pulse length was calibrated and established to be
9.4 µs, with a transmission power of 0 dB. The temperature was kept constant at 300.2 K. The residual
protonated solvent was used as internal reference for the chemical shift scale (CHCl3, δ1H: 7.26 ppm,
δ13C: 77.16 ppm).
The isolation of compounds present in fraction II was carried out on a Waters 2695 Alliance
DAD System HPLC working in reversed phase with a Kinetex C18 column (100 Å pore size, 4.6 mm
ID, 2.6 µm particle size, and 10 cm length, Phenomenex, Italy) using a mobile phase composed of
solvent A, methanol:water (7:3 v/v) with 0.5% formic acid, and solvent B, methanol with 0.5% formic
acid. The elution was performed in a gradient program starting with 70% B and reaching 100% B in
26 min. The isolated analytes ionised well in negative ion mode (S2).
After the preliminary survey, the pooled fractions III-IV were further purified by HPLC, and their
main constituents’ structures were elucidated by NMR (using a combination of 1H, 13C, COSY, HMBC,
and HSQC techniques).
3.7. Microorganisms and Media
For antifungal susceptibility testing, strains from the American Type Culture Collection (ATCC, Manassas,
VA, USA; S. cerevisiae ATCC4040002 and C. albicans ATCC MYA-2876) were used as references.
The environmental strain S. cerevisiae BB1533, and human gut clinical isolates S.cerevisiae YUC5, C. albicans YN5,
C. albicans YN7, C. albicans YL1, C. albicans MFB 076N1, C. albicans MFB008MM1, C. albicans MFBYMS100-3,
C. albicans MFBYMS102-2, C. parapsilosis YB1, C. parapsilosis MFBYMS100-1, C. parapsilosis MFB014CD7,
C. parapsilosis MFB070N1, C. glabrata MFB004, C. glabrata MFB005FS4, C. lusitaniae MFB037-1, C. lusitaniae
MFB022-2, C. lusitaniae MFB YMS100-16, C. intermedia MFB022-1, C. intermedia AD125, C. tropicalis MFB035-1,
C. tropicalis RTT037-3, C. pararugosa MFB037N3, were kindly supplied by Professor Duccio Cavalieri Laboratory
and tested for their susceptibility against the applied drugs.
Yeasts were grown on Sabouraud agarized medium for 48 h at 30 ◦C and resuspended in distilled
water to a concentration of 1–5 × 105 CFU/mL before testing.
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3.8. Antifungal Susceptibility Testings
Yeasts were tested for their susceptibility to H. mexicanum crude extract (8 dilution series, ranging
from 1000 µg/mL to 8 µg/mL) and fractionated extracts (7 dilution series ranging from 125 µg/mL to
2µg/mL), following the European Committee for Antimicrobial Susceptibility Testing protocol (EUCAST
Definitive Document EDef 7.2 Revision, 2012) [35]. Briefly, cells were grown in RPMI1640 medium
supplied with 2% glucose, counted and inoculated at a concentration of 1–5 × 105 CFU/mL. Minimum
inhibitory concentration (MIC) values were determined using a spectrophotometer (at 530 nm) after
48 h and 120 h incubation, as the lowest concentration of the drug that resulted in a ≥50% inhibition of
growth relative to the growth control [35].
3.9. Cytotoxicity Assay
The cytotoxicity of the isolated compounds was tested using the WST-8 (4-[3-(2-methoxy-4-
nitrophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate sodium salt) conversion assay.
The cytotoxicity was evaluated on two normal cell lines, namely PBMC and human foreskin fibroblast
Hs27 (ATCC® CRL-1634™, Manassas, VA, USA). PBMCs were obtained from buffy coat of healthy
donors (as approved by the ethical committee of the local health center, Azienda Provinciale per i Servizi
Sanitari, Provincia Autonoma di Trento) within 4 h from sample collection and isolated as previously
described [9]. Cells were seeded in 96-well culture plates at concentration of 5000 cells/well and
incubated for 24 h before treatment with H. mexicanum extracts and isolated compounds. To measure
the cytotoxic effects 10 µL of Cell Counting Kit-8 (Sigma-Aldrich, St. Louis, MO, USA) (containing
the WST-8 solution) were added to each well and incubated for 2 h and 4 h for fibroblasts and PBMCs
respectively, at 37C before reading the absorbance at 450 nm.
The results were analyzed by Student’s t-test. The data are expressed as the percentage of viability
and standard error of the mean.
3.10. Chemogenomics
Frozen aliquots of Yeast Deletion Heterozygous Diploid Pools (Cat. no.95401.H4Pool) were
recovered for 10 generations and logarithmically growing cells were diluted to a final OD600 of
0,06 (=105 cells/mL) in YPD containing 1% DMSO or compound. The compound was applied at a dose
of 150 µg corresponding to 10–20% wild-type growth inhibition. Cells were grown in a Synergy
2 Multimode Microplate reader (BioTek, Winooski, VT, USA), harvested after 20 generations of
growth and frozen at −20 ◦C for subsequent preparation of DNA. Genomic DNA was purified by
Phenol:Chloroform:Isoamylalcohol extraction (including RNAse digestion). DNA quality was assessed
via agarose gel electrophoresis and UV-Vis spectroscopy. For each condition (control or compound)
4 biological replicates were generated.
A two-step PCR protocol for efficient multiplexing of Bar-seq libraries was applied as previously
described [36] with the following modifications. In a first step, UPTAGs and DNTAGs from a single
sample were amplified using the primers Illumina UPTAG Index and Illumina UPkanMX and Illumina
DNTAG Index and Illumina DNkanMX in separate PCR reactions. Illumina UPTAG and Illumina
DNTAG primers contain a 5-bp sequence that uniquely identifies the sample. A complete list of primer
sequences is provided in Supplementary Materials, Table S5.
Genomic DNA was normalized to 10 ng/mL and 100 ng were used as template for amplification
of barcodes using FastStart High Fidelity PCR system (Roche Diagnostics), applying the following
PCR program: 4 min at 95 ◦C followed by 30 cycles of 30 s at 95 ◦C, 30 s at 50 ◦C, 30 s at 72 ◦C, and
a final extension step of 7 min at 72 ◦C. PCR products were confirmed on 2% agarose gels and purified
using the Agencourt AMPure XP system (Beckman Coulter, Brea, CA, USA).
Purified PCR products were quantified using the Quant-iT dsDNA kit (Invitrogen) and 60 ng from
each of the 4 different UPTAG libraries and, in a separate tube, 60 ng from each of the 4 different DNTAG
libraries were combined. The multiplexed UPTAG libraries were then amplified using the primers
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P5 and Illumina UPkanMX, and the combined DNTAG libraries were amplified using the P5 and
IlluminaDNkanMX primers (Table S5) and the PCR program: 4 min at 95 ◦C followed by 25 cycles of 10
s at 95 ◦C, 10 s at 50 ◦C, 10 s at 72 ◦C, and a final extension step of 3 min at 72 ◦C. The 140-bp UPTAG and
DNTAG libraries were purified using the Agencourt AMPure XP system, quantified using the Quant-iT
dsDNA kit and combined in equimolar amounts. The library was sequenced on an Illumina HiSeq
2000 using standard methods, including the use of the standard Illumina sequencing primer (5′-ACA
CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT-3′). The qseq files for each of the 4 samples are
available from the European Nucleotide Archive EBI-ENA with the accession number PRJEB27820.
3.11. Computational Details
For chemogenomic analysis read matching was performed using an in-house developed Python
script which is available on Github (https://github.com/marcomoretto/Bar-seq). A Levenshtein distance
of two was used to allow mismatches between reads. Reads perfectly matching multiple barcodes
were removed from the analysis. The final count matrix has been obtained summing the UPTAG and
DNTAG, removing barcodes with zeros across all samples and matches with low-count, since they are
more likely due to sequencing noise.
The statistical analysis was performed with the voom transformation [37] package that estimates
the mean–variance relationship of log counts, generating a precision weight for each observation that
is fed into the limma empirical Bayes analysis pipeline [38]. A double threshold based on both p-value
(≤0.01) and expression log2 fold change (≥15) was imposed to identify barcodes differentially abundant
through pairwise comparison (Figure 5).
4. Conclusions
Novel dimeric acylphloroglucinols with potent selective cytotoxicity against pathogenic fungi have
been isolated from a neglected plant species, highlighting the importance of conserving the biodiversity
and investigation of the huge variety of plant derived structures for drug discovery. Genome-wide
mechanism of action analysis allowed us to suggest novel potential drug targets for the development
of antifungal therapies.
Taken together our results encourage further studies for the discovery and synthesis of dimeric
acylphloroglucinol-based drugs as possible new leads in the antifungal pipeline.
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